From CancerNetwork:
“Men with metastatic castrate resistant prostate cancer (mCRPC) with undetectable circulating tumor counts (CTCs) were 6.1-fold more likely to have complete response to hormonal therapy, according to findings presented at the 2020 ASCO Virtual Scientific Program.
Results from SWOG S1216, a phase III randomized trial, demonstrated that CTC count at treatment initiation was highly prognostic of 7-month prostate specific antigen (PSA) response.
In an interview with CancerNetwork, lead study author Amir Goldkorn, MD of the University of Southern California Keck School of Medicine discussed the next steps for the trial., and what the results could mean moving forward.”
